Prothrombotic disorders in patients with mesenteric vein thrombosis

Journal of Investigative Surgery

Volumn 16, Issue 5, 2003, Pages 299-304

  Aǧaoǧlu, Nazim ^a   Türkyilmaz, Serdar ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Mesenteric vein; Prothrombotic disorders; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ANTITHROMBIN III DEFICIENCY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MESENTERIC VEIN THROMBOSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SCREENING TEST;

EID: 0242636379     PISSN: 08941939     EISSN: None     Source Type: Journal    
DOI: 10.1080/713829710     Document Type: Article

References (52)

1. Clavien PA, Durig M, Harder F. Venous mesenteric infarction: A particular entity. Br J Surg. 1988;75:252-255.
2. Rhee RY, Gloviczki P, Mendonca CT, et al. Mesenteric venous thrombosis: Still a lethal disease in the 1990s. J Vasc Surg. 1994;20:688-697.
3. Alam H, Kim D, Provido H, Kirkpatrick J. Portal vein thrombosis in the adult: Surgical implications in an era of dynamic imaging. Am Surg. 1997;63:681-684.
4. Uttenreuther-Fischer MM, Vetter B, Hellmann C, et al. Pediatric thrombo-embolism: The influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Pediatr. 1997;156:277-281.
5. Chen MC, Brown MC, Willson RA, Nicholls S, Surawicz CM. Mesenteric vein thrombosis. Four cases and review of the literature. Dig Dis. 1996;14:382-389.
6. Kim DI, Lee BB, Noh SI, et al. Conservative management of superior mesenteric and portal vein thrombosis associated with protein C and S deficiency. Case report. Int Angiol. 1997;16:235-238.
7. Markis M, Rosendaal FR, Preston FE. Familial thrombophilia: Genetic risk and management. J Intern Med Suppl. 1997;740:9-15.
8. Bertina M. Factor V Leiden and other coagulation factor mutation affecting thrombotic risk. Clin Chem. 1997;43:1678-1683.
9. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;15:3698-3703.
10. Biousse V, Conard J, Brouzes C, et al. Frequency of the 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene in 35 cases of cerebral venous thrombosis. Stroke. 1998;29:1398-1400.
11. Kapur RK, Millis LA, Spitzer SG, et al. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol. 1997;17:2875-2879.
12. Brown K, Luddington R, Williamson D, et al. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol. 1997;98:907-909.
13. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant, Ann Intern Med. 1998;129:89-93.
14. Margaglione M, D'Andrea G, d'Addedda M, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost. 1998;79:907-911.
15. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vasc Biol. 1996;16:742-748.
16. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: An unrecognized diagnosis. Am J Med. 1997;102:14-20.
17. Mossier C, Kerbl R, Wagner T, Muntean W, Sorantin E, Urban CE. Portal vein thrombosis in a 17-year-old female adolescent with essential thrombocytosis. Pediatr Hematol Oncol. 1997;14:457-462.
18. Klempnauer J, Grothues F, Bektas H, Pichlmayr R. Longterm results after surgery for acute mesenteric ischaemia. Surgery. 1997;121:239-243.
19. Sachs SM, Morton JH, Schwartz SI. Acute mesenteric ischaemia. Surgery. 1982;92:646-653.
20. Grendell J, Ockner RK. Mesenteric vein thrombosis. Gastroenterology. 1982;82:358-372.
21. Maloisel F. Role of coagulation disorders in mesenteric ischemia. J Chir. 1996;133:442-447.
22. Fair DS, Marlar SA. Biosynthesis and secretion of factor VII, protein C, protein S and protein C inhibitor from a human hepatoma cell line. Blood. 1986;67:64-70.
23. Stenflo J. A new vitamin K-dependent protein: Purification from bovine plasma and preliminary characterization. J Biol Chem. 1976;251:355-363.
24. Walker JF. Regulation of activated protein C by protein S. J Biol Chem. 1981;256:1128-1131.
25. Comp PC, Esmon CT. Activated protein C inhibits platelet prothrombin-converting activity. Blood. 1979;54:1272-1281.
26. Grundy CB, Melissari E, Lindo V, Scully MF, Kakkar VV, Cooper DN. Late-onset homozygous protein C deficiency. Lancet. 1991;338:575-576.
27. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med. 1983;309:340-344.
28. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984;31:559-562.
29. Schafer AI, Kroll MH. Nonatheromatous arterial thrombosis. Annu Rev Med. 1993;44:155-170.
30. Egeberg O. Inherited anti-thrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
31. Van Boven HH, Vandenbroucke JP, Brïet E, Rosendaal FR. Gene-gene and gene-environment interactions determine the risk of thrombosis in families with inherited anti-thrombin deficiency. Blood. 1999;94:2590-2594.
32. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
33. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 52 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.
34. Zöller PJ, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538.
35. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
36. Amitrano L, Branacaccio V, Guardascione MA, et al. High prevalence of thrombophilic genotypes in patients with mesenteric vein thrombosis. Am J Gastroenterol. 2001;96:146-149.
37. Gurgey A, Hamzedaroǧlu IC, Egesel T, et al. Two common genetic thrombotic risk factors: Factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol. 2001;67:107-111.
38. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503-1506.
39. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128:15-20.
40. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508.
41. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997;196:412-417.
42. Ma J, Stampter MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in U.S. physicians. Circulation. 1996;94:2410-2416.
43. Arruda VR, von Zuden PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala 677Val in the methylenetetrahydrofolate gene: A risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997;77:818-821.
44. Maurizio M, Giovanna DA, Marina DA, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the factor V Leiden and the prothrombin A20210 mutation. Thromb Haemost. 1998;79:907-911.
45. Salomer O, Dardik R, Zivelin A, et al. Homozygous methylenetetrahydrofolate reductase thermolability (MTHFR) is an independent risk factor for idiopathic deep vein thrombosis. Thromb Haemost Suppl. 1997; 568.
46. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Serra FG, Bizzi B, Leone G. Prevalence of factor V 1691 G to A and methylenetetrahydrofolate reductase 677 C to T mutated gene in patients with venous thrombosis. Thromb Haemost Suppl. 1997;569.
47. Rintelen C, Pabinger I, Leckner K, Eichinger S, Kyrie PA, Mannhalter C. No evidence for an increase of the risk of venous thrombosis in patients with factor V Leiden by the homozygous mutation in the methylenetetrahydrofolate gene. Thromb Haemost Suppl. 1997;569.
48. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA projects C677T mutation in the methylenetetrahydrofolate reductase gene and risk of venous thromboembdism. Br J Haematol. 1997;97:804-806.
49. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995;74:449-453.
50. Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol. 1997;34:171-187
51. Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res. 2000;99:447-452.
52. Comp PC. Laboratory evaluation of protein S status. Semin Thromb Hemost. 1990;16:177-181.